SCHEMBL10195696

SCHEMBL10195696

CC(=O)N1CCN(C(=O)c2ccc(-n3cc(-c4n[nH]c5ccccc45)nn3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
MAPK10 P53779 9/20 0.46
CHEK1 O14757 2/20 0.44
GRM4 Q14833 1/20 0.44
CDK1 P06493 2/20 0.44
CCNB1 P14635 2/20 0.44
MAPK8 P45983 7/20 0.43
BMPR1B O00238 1/20 0.42
PLK4 O00444 1/20 0.42
STK25 O00506 1/20 0.42
CIT O14578 1/20 0.42
RIOK3 O14730 1/20 0.42
IKBKB O14920 1/20 0.42
AURKA O14965 1/20 0.42
GAK O14976 1/20 0.42
DCLK1 O15075 1/20 0.42
CHUK O15111 1/20 0.42
MUSK O15146 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10194782 0.91 MAPK10 (0.53) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL10195027 0.90 MAPK10 (0.46) FLT3ALDH1A1MAPTMAPK10MAPK8
SCHEMBL10195701 0.90 FLT3 (0.53) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL10194947 0.89 ALDH1A1 (0.45) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL10195024 0.89 MAPK10 (0.52) FLT3ALDH1A1MAPTMAPK10MAPK8
SCHEMBL10194768 0.88 FLT3 (0.55) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL9953219 0.87 MGLL (0.44) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL10194974 0.87 IDO1 (0.45) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL10194945 0.86 L3MBTL3 (0.49) FLT3ALDH1A1MAPTMAPK10CHEK1
SCHEMBL10194958 0.85 MAP2K4 (0.41) FLT3ALDH1A1MAPTMAPK10CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES NFATC1, IL5, CD4 FLT3 282/4885ALDH1A1 875/4885MAPT 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.